Morgan Stanley raised the firm’s price target on Gilead (GILD) to $135 from $130 and keeps an Overweight rating on the shares. The company delivered a generally in line Q1 and reiterated 2025 guidance, while also noting that FDA interactions regarding lenacapavir for PREP are on track, the analyst tells investors. The firm sees the potential for upward estimate revisions on lenacapavir and further multiple expansion as the company progresses its next-generation HIV pipeline, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strong Core Business and Growth Potential Amid Valuation Opportunities
- Gilead Sciences: Hold Rating Amid Mixed Performance and Future Opportunities
- Gilead Sciences: Strong Growth Prospects and Strategic Positioning Support Buy Rating
- Gilead Sciences Reports Strong Start to 2025
- Closing Bell Movers: Alphabet up 5% after earnings beat